2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market information and celebrate the successful collaboration in the p
Visit AmoyDx at AMP Annual Meeting 2018 in USA
AmoyDx Exhibits in AMP Annual Meeting 2018 (1-3 November, San Antonio, USA) and shows a novel and accurate approach for simultaneous detection of multiple driver gene mutations in NSCLC.
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China) Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA（National Medical Products Administration）approved AmoyDx Super-ARMS® EGFR mutation test kit